Edwin Lee

Coverage status — October 2026: Lee is the peptide-access movement’s most credentialed organizer: a practicing endocrinologist who presents clinical evidence to regulators and, simultaneously, built the campaign’s petition infrastructure. He was a lead clinician voice quoted across the July 2026 coverage of the FDA’s Pharmacy Compounding Advisory Committee (PCAC) proceedings.

His record, as he and his bios present it: board-certified endocrinologist and Assistant Professor at the UCF College of Medicine, practicing at the Institute for Hormonal Balance in Orlando; author of The Fountain of Youth with Peptides; co-founder of the Clinical Peptide Society. His Rupa Health bio credits him with the first human trial of BPC-157 injected into the knee — a claim this site attributes to his bio, not to the published literature. In his teaching (BPC-157, thymosin alpha-1, kisspeptin-10, growth-hormone secretagogues, and bioregulators), he explicitly notes where human trials are absent and flags risks such as anaphylaxis — caveats that appear in his own interviews, not just his critics'.

The dual role, stated plainly: Lee is both an evidence presenter and the access campaign’s organizer. SavePeptides.org, the advocacy nonprofit he founded, drew roughly 10,000 petition signatures (AFP), and his own practice offers peptides. His regulatory advocacy and his clinic’s interest point the same direction; this site reports both, and attributes his evidence claims to him.

Why tracked here: the FDA’s peptide-compounding decision will be shaped by whoever regulators find credible — and Lee is the figure who combines the endocrinology credentials, a human-trial claim on the record, and the organized petition behind the testimony.

Sources (Oct 2026): AFP (SavePeptides.org petition, ~10,000 signatures); Rupa Health biography (first human BPC-157 knee trial claim); UCF College of Medicine and Institute for Hormonal Balance listings; July 2026 PCAC coverage.